Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe Locations entry changed from Napoli, Italy, 80147 to Naples, Italy, 80147.SummaryDifference0.0%

- Check15 days agoChange DetectedAdded a new resource entry for the Genetic and Rare Diseases Information Center under Resources. Updated the revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check31 days agoChange DetectedThe Study Results section now shows 'Results Submitted' instead of 'No Results Posted'. This indicates that results have been submitted for the trial.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page revision is updated from v3.4.1 to v3.4.2, with no changes to core study details or patient information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedAdded detailed patient-reported outcome (PRO) endpoints, including EORTC QLQ-C30 and QLQ-HCC18 measures and time-to-deterioration metrics for quality of life and symptoms. Also removed older PRO descriptions and certain administrative notices from the page.SummaryDifference0.7%

Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.